Adherence to tobramycin inhaled powder vs inhaled solution in patients with cystic fibrosis: analysis of US insurance claims data

References

• KnowlesMRDuriePRWhat is cystic fibrosis?N Engl J Med2002347643944212167688
   PubMed Web of Science ®Google Scholar
• FlumePAPulmonary complications of cystic fibrosisRespir Care200954561862719393106
   PubMed Web of Science ®Google Scholar
• Cystic Fibrosis Foundation Patient Registry. 2015 Annual Data ReportBethesda, MDCystic Fibrosis Foundation2016
   Google Scholar
• PotronAPoirelLNordmannPEmerging broad-spectrum resistance in Pseudomonas aeruginosa and Acinetobacter baumannii: mechanisms and epidemiologyInt J Antimicrob Agents201545656858525857949
   PubMed Web of Science ®Google Scholar
• PooleKPseudomonas aeruginosa: resistance to the maxFront Microbiol201126521747788
   PubMed Web of Science ®Google Scholar
• McCoyKSQuittnerALOermannCMGibsonRLRetsch-BogartGZMontgomeryABInhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosisAm J Respir Crit Care Med2008178992192818658109
   PubMed Web of Science ®Google Scholar
• Retsch-BogartGZQuittnerALGibsonRLEfficacy and safety of inhaled aztreonam lysine for airway pseudomonas in cystic fibrosisChest200913551223123219420195
   PubMed Web of Science ®Google Scholar
• RamseyBWPepeMSQuanJMIntermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study GroupN Engl J Med1999340123309878641
   PubMed Web of Science ®Google Scholar
• RyanGSinghMDwanKInhaled antibiotics for long-term therapy in cystic fibrosisCochrane Database Syst Rev20113CD00102121412868
   PubMed Web of Science ®Google Scholar
• SawickiGSSellersDERobinsonWMHigh treatment burden in adults with cystic fibrosis: challenges to disease self-managementJ Cyst Fibros200982919618952504
   PubMed Web of Science ®Google Scholar
• BodnárRMészárosAOláhMÁghTInhaled antibiotics for the treatment of chronic Pseudomonas aeruginosa infection in cystic fibrosis patients: challenges to treatment adherence and strategies to improve outcomesPatient Prefer Adherence20161018319326937178
   PubMed Web of Science ®Google Scholar
• QuittnerALZhangJMarynchenkoMPulmonary medication adherence and health-care use in cystic fibrosisChest2014146114215124480974
   PubMed Web of Science ®Google Scholar
• BriesacherBAQuittnerALSaimanLSaccoPFouayziHQuittellLMAdherence with tobramycin inhaled solution and health care utilizationBMC Pulm Med201111521251275
   PubMed Web of Science ®Google Scholar
• SmythARBellSCBojcinSEuropean cystic fibrosis society standards of care: best practice guidelinesJ Cyst Fibros201413Suppl 1S23S4224856775
   PubMed Web of Science ®Google Scholar
• GellerDEWeersJHeuerdingSDevelopment of an inhaled dry-powder formulation of tobramycin using PulmoSphere™ technologyJ Aerosol Med Pulm Drug Deliv201124417518221395432
   PubMed Web of Science ®Google Scholar
• KonstanMWFlumePAKapplerMSafety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: the EAGER trialJ Cyst Fibros2011101546121075062
   PubMed Web of Science ®Google Scholar
• SomayajiRParkinsMDTobramycin inhalation powder: an efficient and efficacious therapy for the treatment of Pseudomonas aeruginosa infection in cystic fibrosisTher Deliv201662121137
   Google Scholar
• LamJVaughanSParkinsMDTobramycin inhalation powder (TIP): an efficient treatment strategy for the management of chronic Pseudomonas aeruginosa infection in cystic fibrosisClin Med Insights Circ Respir Pulm Med20137617724324354
   PubMedGoogle Scholar
• LittlewoodKJHigashiKJansenJPA network meta-analysis of the efficacy of inhaled antibiotics for chronic Pseudomonas infections in cystic fibrosisJ Cyst Fibros201211541942622717535
   PubMed Web of Science ®Google Scholar
• GreenbergJPalmerJBChanWWTreatment satisfaction in cystic fibrosis: early patient experience with tobramycin inhalation powderPatient Prefer Adherence2016102163216927822017
   PubMed Web of Science ®Google Scholar
• HarrisonMJMcCarthyMFlemingCInhaled vs nebulised tobramycin: A real world comparison in adult cystic fibrosis (CF)J Cyst Fibros201413669269824815094
   PubMed Web of Science ®Google Scholar
• HamedKDebonnettLTobramycin inhalation powder for the treatment of pulmonary Pseudomonas aeruginosa infection in patients with cystic fibrosis: a review based on clinical evidenceTher Adv Respir DisIn press2016
   Web of Science ®Google Scholar
• ModiACLimCSYuNGellerDWagnerMHQuittnerALA multi-method assessment of treatment adherence for children with cystic fibrosisJ Cyst Fibros20065317718516679071
   PubMed Web of Science ®Google Scholar
• DanielsonEHealth research data for the real world: the MarketScan Databases. White PaperTruven Health AnalyticsAnn Arbor, MI2014
   Google Scholar
• OuyangLGrosseSDAmendahDDSchechterMSHealthcare expenditures for privately insured people with cystic fibrosisPediatr Pulmonol2009441098999619768806
   PubMed Web of Science ®Google Scholar
• WhiteTMillerJSmithGLMcMahonWMAdherence and psychopathology in children and adolescents with cystic fibrosisEur Child Adolesc Psychiatry20091829610418807223
   PubMed Web of Science ®Google Scholar
• DiMatteoMRLepperHSCroghanTWDepression is a risk factor for noncompliance with medical treatment: meta-analysis of effects of anxiety and depression on patient adherenceArch Intern Med2000160142101210710904452
   PubMed Web of Science ®Google Scholar
• CoutoJEPanchalJMLalLSGeographic variation in medication adherence in commercial and Medicare part D populationsJ Manag Care Spec Pharm201420883484225062077
   PubMed Web of Science ®Google Scholar
• RegnaultABalpMMKulichKViala-DantenMValidation of the treatment satisfaction questionnaire for medication in patients with cystic fibrosisJ Cyst Fibros201211649450122583743
   PubMed Web of Science ®Google Scholar
• SawickiGSRenCLKonstanMWMillarSJPastaDJQuittnerALInvestigators and Coordinators of the Epidemiologic Study of Cystic FibrosisTreatment complexity in cystic fibrosis: trends over time and associations with site-specific outcomesJ Cyst Fibros201312546146723352205
   PubMed Web of Science ®Google Scholar
• DiMatteoMRLepperHSCroghanTWDepression is a risk factor for noncompliance with medical treatment: meta-analysis of effects of anxiety and depression on patient adherenceArch Intern Med2000160142101210710904452
   PubMed Web of Science ®Google Scholar